Medicis to Present At Goldman Sachs Global Healthcare Conference

SCOTTSDALE, Ariz., June 6, 2008 (PRIME NEWSWIRE) -- Medicis (NYSE:MRX) today
announced that the Company is scheduled to present at the Goldman Sachs 29th
Annual Global Healthcare Conference in Dana Point, California. A live webcast of
its presentation scheduled for Tuesday, June 10, 2008, at 12:50 p.m. Eastern
Time (9:50 a.m. Pacific Time), may be accessed via the Internet.

The webcast will be available via a link on the Medicis corporate website at
http://www.medicis.com/company/index.asp. This link will allow visitors to the
website to access the Medicis presentation. An archive of the webcast will be
available on the Medicis corporate website for two business days following the
live presentation.

About Medicis

Medicis is the leading independent specialty pharmaceutical company in the
United States focusing primarily on the treatment of dermatological and
aesthetic conditions. The Company is dedicated to helping patients attain a
healthy and youthful appearance and self-image. Medicis has leading branded
prescription products in a number of therapeutic and aesthetic categories. The
Company's products have earned wide acceptance by both physicians and patients
due to their clinical effectiveness, high quality and cosmetic elegance.

The Company's products include the prescription brands RESTYLANE(R) (hyaluronic
acid), PERLANE(R) (hyaluronic acid), DYNACIN(R) (minocycline HCl), LOPROX(R)
(ciclopirox), PLEXION(R) (sodium sulfacetamide/sulfur), SOLODYN(R) (minocycline
HCl, USP) Extended Release Tablets, TRIAZ(R) (benzoyl peroxide), LIDEX(R)
(fluocinonide) Cream, 0.05%, VANOS(R) (fluocinonide) Cream, 0.1%, and ZIANA(R)
(clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, BUPHENYL(R) (sodium
phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate),
prescription products indicated in the treatment of Urea Cycle Disorder, and the
over-the-counter brand ESOTERICA(R). For more information about Medicis, please
visit the Company's website at www.medicis.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act. All statements included in this
press release that address activities, events or developments that Medicis
expects, believes or anticipates will or may occur in the future are
forward-looking statements. These statements are based on certain assumptions
made by Medicis based on its experience and perception of historical trends,
current conditions, expected future developments and other factors it believes
are appropriate in the circumstances. No assurances can be given, however, that
these activities, events or developments will occur or that such results will be
achieved. Such statements are subject to a number of assumptions, risks and
uncertainties, many of which are beyond the control of Medicis. Several of these
risks are outlined in the Company's most recent annual report on Form 10-K for
the year ended December 31, 2007, and other documents we file with the
Securities and Exchange Commission. Forward-looking statements represent the
judgment of Medicis' management as of the date of this release, and Medicis
disclaims any intent or obligation to update any forward-looking statements
contained herein, which speak as of the date hereof.

NOTE: Full prescribing information for any Medicis prescription product is
available by contacting the Company. RESTYLANE(R) and PERLANE(R) are trademarks
of HA North American Sales AB, a subsidiary of Medicis Pharmaceutical
Corporation. All other marks are the property of Medicis or its affiliates.

-0-
CONTACT: Medicis
Kara Stancell
(480) 291-5854